- Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Interventions
- Setmelanotide
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced May 22, 2026, 12:02 AM EDT